{"name":"Bicycle Therapeutics plc","slug":"bicycle","ticker":"BCYC","exchange":"NASDAQ","domain":"bicycletherapeutics.com","description":"Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceu","hq":"Cambridge, UK","founded":0,"employees":"288","ceo":"Kevin Lee","sector":"Oncology Biotech","stockPrice":4.72,"stockChange":-0.02,"stockChangePercent":-0.42,"marketCap":"$330M","metrics":{"revenue":72586000,"revenueGrowth":1193.3,"grossMargin":-215.6,"rdSpend":240283000,"netIncome":-218960000,"cash":628110016,"dividendYield":0,"peRatio":-2.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"BT1718 patent cliff ($0.0B at risk)","drug":"BT1718","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"BT5528 patent cliff ($0.0B at risk)","drug":"BT5528","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Bicycle Therapeutics plc Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"BCYC reported its Q4 and FY 2023 financial results, highlighting a net loss of $43.4 million and a cash balance of $143.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-07","type":"deal","headline":"Bicycle Therapeutics plc Announces Collaboration with Merck KGaA to Develop Novel Therapeutics","summary":"BCYC entered into a collaboration with Merck KGaA to develop and commercialize novel therapeutics for the treatment of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Bicycle Therapeutics plc Announces Positive Interim Results from Phase 1/2 Clinical Trial of BT5528","summary":"BCYC announced positive interim results from a Phase 1/2 clinical trial of BT5528, a novel therapeutic candidate for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNOHlKYTBfZTV0TF9NbmFBeFNwOVhLSktrWEtwYU00Q3I1YmtsVUFDbXRvTkFRbTNUVzF1b1hLZkVqRlUySG82ZmZzTTNRMFVncXVUUHhEVlVja1QwaXZMcEttRjI1VmFwV3pJdlczOVZHM3JmcnNVWTN3ZldWMnpnLWF5ak54Nm51RXpDQUV2bTlIMzd5N25ZQW5jbFVmeFg2QUhPSFFVMDZRRGFOUHpsNF9lSEgycFZ3ZWdF?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Bicycle Therapeutics lines up 400 tonnes of uranium for new radiotherapies - Stock Titan","headline":"Bicycle Therapeutics lines up 400 tonnes of uranium for new radiotherapies","sentiment":"neutral"},{"date":"2026-03-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOYThtRlpCZkNXT2xhdVJuLWhzalFudHdSUy1XdWNwdmZ6bWVSTDV6eEhfWDdRTmxTMXBIX3JoVWU1MkRMdnBjaWx1N3FWTFh1WldfdnhRa282WE1tVjlSYU1uLVotemJUa05NY2lIcGNkZVg5Ty1fcWhCZUtIY2VaQnRiazhITVZtX01NaU1Nc1BOMW9xenlMSGpIUUJZY0l2WkgwT1dva2tibU83N2x0ekxWWkc5Uzdyd2J5OUZ5MXdsV2lWV2dwY00xTlJucmZEQ0VFX2xDQXFSLVc1bmx5am8zV25Nb0NMM0p2c1hFaE9hcHBHNWhF?oc=5","date":"2026-02-03","type":"trial","source":"Business Wire","summary":"Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - Business Wire","headline":"Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQMnNEQnluTGpHOU4zd210OUZVQmtMS0dGNTFMMFFTNF9lNHIxa25yd1BaOE9VT0R1ei1OVmNvNDNtX3Z5RHQyRk1jWlQ5SWpEQm5XQ0s1NVlxT1RMbjBIWTJuTEo0NDRPN21XVDNYcXd6WXBwODB6dkRDc01zZmlFOXlaR1JyeWFkakw5U0QxY3UwM19SYndxWDBsVXhVNEgyVmZPZWtKLXRMOGU2S0pHcl8wcmYwUEZYeWJKSHowbHZDMjNM?oc=5","date":"2026-01-12","type":"pipeline","source":"BioSpace","summary":"Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 - BioSpace","headline":"Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNUE92WG5qUWQ3ZWt4RTNOWEN4bDdYUWprU2RIY0ZXM21pYjAwRjBzbDlUdkRtakdSWnBvemdNYTBmWVJtWXk1SjZwVlJMWmVpdEtjNGtBMXB4bTM5VV9rcFhXTkFlVlAwTVlUNUFBZzJuOTBkVHNhR1M2dEJmaERmbUcwczhZbUFEVUVMa0c1Ri1BaDdnYXBLVDRfMmxQTGJXeGNaLU1UNXpnYllrWm94S24zZHhYTnlQS191Q1R0cjJId1B4cFBMbGdCdjNyLUUzektwU2Y3WUlNQlIybnhGYmNxZTlKcjlsY2lBQVN1YWdEQjF1cUw0TlJ5bTRtZ09jbWEzdGZyZVI1aGtmTV9vSUE2ckQ2OXJqTjctN2hjb0NKZC1zendPYUtmYVh2c3lZdTdyVnVncw?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline - Business Wire","headline":"Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQc3pLOEJjQVpNTTZTdFpJbjh3d1JKb1R0WkFWazU4NTVkQVctNW9hYTUxMGplaHRjTkphcVV1T0NEakNtNjhHbGJhQ2FNcU02SDZscHF4bUNLTHJCLXVrNjdvUW96YnlhOFBZYTNNQXlhSGJRT250QTRGbUZybGRsOEZfVXR3bS10V0hLUXFranR1S3JaQnFMTmsyTjV1RG9tTVpRMFN3SUsyUTZBWDNZZTRNWGFlRmxLSmM1ak9yRk1QMHZDMS1SN1FYZnFTNkNFWmZOdlVpRFJnblZfUEN6U2s0ZHJJQQ?oc=5","date":"2025-10-30","type":"earnings","source":"Business Wire","summary":"Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Business Wire","headline":"Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNSjBwZnQ5NU1QRnU5clRPeHZ5ZFRWX0UyZElTU3ZnV2J4YVhyU0JQV0duTG9GZ2phRm9LTGRzQXhsT1pYR2ZzNVFYZV9uQktWLWR6LW5aWFZ1TVc5RFJUU3RMT3ZYZTZSajlxbFl0ZkhxZWotWUk4YW81SG1EanVNQklKeXRicUJheWVlNkNKSDRUMm5WNE9rX3ZIRU9mR2RIb3Jqb1FCSHowTVdxLXZWc1hha3pZdVp4RC0zdmNZZw?oc=5","date":"2025-09-08","type":"pipeline","source":"citybiz","summary":"Bicycle Therapeutics Appoints Roger Dansey and Hervé Hoppenot to Board of Directors - citybiz","headline":"Bicycle Therapeutics Appoints Roger Dansey and Hervé Hoppenot to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1LZ0pBNThHNTJvZ3dCUERvSTgySENxUFZuWU5qQ2xuZTFMTDV5Vm53SXItM0xSdHNrX3Y0MHlsMDBqbm40VVY1clkxMTJGYkR6RjJR?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"BCYC Stock Price, News & Analysis - Stock Titan","headline":"BCYC Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1ieTdMV0p5aDE3OFRpU2txb2NmTjhla1AzUk9wMUo3M2x2bFdBdUU3eUx4UHhCN01fQ1RMTFNDUlNjMzZPOWdvSzAxb3kxQU5Q?oc=5","date":"2024-03-07","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSkFVX3lxTFBycTJXNXZGaVhJbXBfeEJQVUtGdVQ1Yzh6eUpwazliY19xMEVlYzJPWklHd3FiVGtHbjYzdlhzQ1dkVkRMLS1TZlpn?oc=5","date":"2021-08-29","type":"pipeline","source":"eToro","summary":"BCYC Stock Price | Analyst Target 16.50 & Consensus - eToro","headline":"BCYC Stock Price | Analyst Target 16.50 & Consensus","sentiment":"neutral"}],"patents":[{"drugName":"BT1718","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0},{"drugName":"BT5528","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Merck & Co.","Bristol-Myers Squibb"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":72586000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":72586000,"period":"2025-12-31"},{"value":35275000,"period":"2024-12-31"},{"value":35275000,"period":"2024-12-31"},{"value":26976000,"period":"2023-12-31"},{"value":26976000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":240283000,"rdSpendHistory":[{"period":"2025-12-31","value":240283000},{"period":"2024-12-31","value":172966000},{"period":"2023-12-31","value":156496000},{"period":"2022-12-31","value":81609000}],"sgaSpend":80021000,"operatingIncome":-247718000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-247718000},{"period":"2024-12-31","value":-209153000},{"period":"2023-12-31","value":-189946000},{"period":"2022-12-31","value":-116653000}],"netIncome":-218960000,"netIncomeHistory":[{"period":"2025-12-31","value":-218960000},{"period":"2024-12-31","value":-169031000},{"period":"2023-12-31","value":-180664000},{"period":"2022-12-31","value":-112717000}],"eps":-3.16,"epsHistory":[{"period":"2025-12-31","value":-3.16},{"period":"2024-12-31","value":-2.9},{"period":"2023-12-31","value":-5.08},{"period":"2022-12-31","value":-3.8}],"cash":628110000,"cashHistory":[{"period":"2025-12-31","value":628110000},{"period":"2024-12-31","value":879520000},{"period":"2023-12-31","value":526423000},{"period":"2022-12-31","value":339154000}],"totalAssets":717597000,"totalLiabilities":107620000,"totalDebt":16852000,"equity":609977000,"operatingCashflow":-249675000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-249675000},{"period":"2024-12-31","value":-164724000},{"period":"2023-12-31","value":-60628000},{"period":"2022-12-31","value":-86111000}],"capex":-2350000,"capexHistory":[{"period":"2025-12-31","value":-2350000},{"period":"2024-12-31","value":-1235000},{"period":"2023-12-31","value":-2929000},{"period":"2022-12-31","value":-18987000}],"freeCashflow":-252025000,"dividendsPaid":null,"buybacks":null,"employees":288,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17575000,"ebit":-60605000,"ebitda":-59476000,"period":"2026-03-31","revenue":887000,"epsBasic":-0.87,"netIncome":-60825000,"rdExpense":48901000,"epsDiluted":-0.87,"grossProfit":null,"operatingIncome":-65589000},{"sga":20842000,"ebit":-18832000,"ebitda":-17496000,"period":"2025-12-31","revenue":47955000,"epsBasic":-0.29,"netIncome":-20154000,"rdExpense":51770000,"epsDiluted":-0.29,"grossProfit":null,"operatingIncome":-24657000},{"sga":19017000,"ebit":-58851000,"ebitda":-57095000,"period":"2025-09-30","revenue":11734000,"epsBasic":-0.85,"netIncome":-59100000,"rdExpense":58426000,"epsDiluted":-0.85,"grossProfit":null,"operatingIncome":-65709000},{"sga":19238000,"ebit":-79129000,"ebitda":-77433000,"period":"2025-06-30","revenue":2920000,"epsBasic":-1.14,"netIncome":-78952000,"rdExpense":71029000,"epsDiluted":-1.14,"grossProfit":null,"operatingIncome":-87347000},{"sga":20924000,"ebit":-61790000,"ebitda":-60156000,"period":"2025-03-31","revenue":9977000,"epsBasic":-0.88,"netIncome":-60754000,"rdExpense":59058000,"epsDiluted":-0.88,"grossProfit":null,"operatingIncome":-70005000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.72,"previousClose":4.74,"fiftyTwoWeekHigh":9.36,"fiftyTwoWeekLow":4.24,"fiftyTwoWeekRange":"4.24 - 9.36","fiftyDayAverage":4.9,"twoHundredDayAverage":6.5,"beta":1.65,"enterpriseValue":-282240832,"forwardPE":-2.2,"priceToBook":0.54,"priceToSales":4.54,"enterpriseToRevenue":-3.89,"enterpriseToEbitda":1.19,"pegRatio":0,"ebitda":-236443008,"ebitdaMargin":0,"freeCashflow":-121572376,"operatingCashflow":-249675008,"totalDebt":16852000,"debtToEquity":2.8,"currentRatio":11.98,"returnOnAssets":-18.1,"returnOnEquity":-31.2,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":12.11,"targetHighPrice":36,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.4,"institutionHeldPercent":73.2,"sharesOutstanding":50373281,"floatShares":0,"sharesShort":2635218,"shortRatio":4.45,"shortPercentOfFloat":3.8,"epsTrailing":-3.15,"epsForward":-2.13,"revenuePerShare":1.05,"bookValue":8.79,"officers":[{"age":57,"name":"Dr. Kevin  Lee M.B.A., Ph.D.","title":"CEO & Executive Director"},{"age":74,"name":"Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.","title":"Co-Founder & Independent Non-Executive Director"},{"age":56,"name":"Dr. Michael  Skynner B.sc. Ph.d., Ph.D.","title":"Chief Scientific Officer"},{"age":51,"name":"Mr. Alistair  Milnes","title":"Chief Corporate Development Officer"},{"age":null,"name":"Dr. Christian  Heinis","title":"Scientific Founder"},{"age":45,"name":"Mr. Travis  Thompson","title":"Chief Financial Officer"},{"age":51,"name":"Dr. Jennifer  Perry Pharm.D.","title":"Chief Operating Officer"},{"age":null,"name":"Ms. Stephanie  Yao","title":"Senior Vice President of Investor Relations and Corporate Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.bicycletherapeutics.com","phone":"44 1223 261 503"}}